Canada Launches ‘More Responsive’ Post-Marketing Drug Evaluation Program
Executive Summary
Canada’s health technology appraisal body, CADTH, has launched a new program that will harness real-world evidence to provide more information and advice on the safety and effectiveness of drugs that are already approved.
You may also be interested in...
Canada Builds On RWE Guidance
Industry representatives are invited to join a new task force to help advise on how industry-gathered real-world evidence should be used in regulatory and health technology assessment decision making.
Canada Consults On Real-World Evidence Guidance For HTAs And Regulators
Canada’s health technology appraisal body is seeking feedback on guidance on the use of real-world evidence in decision making.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.